Exelixis Inc. Stock
Price
Target price
€35.07
€35.07
-0.490%
-0.17
-0.490%
€38.01
20.06.25 / Tradegate
WKN: 936718 / Symbol: EXEL / Name: Exelixis / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
Exelixis Inc. Stock
Exelixis Inc. shows a slight decrease today, losing -€0.170 (-0.490%) compared to yesterday.
The stock is an absolute favorite of our community with 39 Buy predictions and no Sell predictions.
As a result the target price of 38 € shows a slightly positive potential of 8.35% compared to the current price of 35.07 € for Exelixis Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Exelixis Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Exelixis Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Exelixis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Exelixis Inc. | -0.490% | -2.583% | -10.763% | 74.564% | 7.445% | 96.713% | 62.851% |
| Ironwood Pharmaceuticals | -1.650% | 5.310% | 5.310% | -88.774% | -85.833% | -94.501% | -93.200% |
| Arrowhead Pharmaceuticals Inc. | -1.780% | -2.459% | -8.059% | -40.162% | -28.143% | -52.485% | -59.476% |
| Novocure Ltd | -2.670% | -6.902% | -9.325% | -18.942% | -49.742% | -73.730% | -74.152% |
Comments
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at HC Wainwright from $40.00 to $47.00. They now have a "buy" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Citigroup Inc. from $45.00 to $56.00. They now have a "buy" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $40.00 price target on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
News
2 Top Stocks to Buy With Less Than $100
When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that
Why Exelixis Stock Is Skyrocketing Today
Shares of Exelixis (NASDAQ: EXEL) were skyrocketing 18.5% higher at 11:05 a.m. ET on Wednesday. The huge gain came after the drugmaker announced its 2025 first-quarter results Tuesday evening.
Exelixis Stock: Executives Sell as Shares Near Peak
Exelixis is experiencing significant insider selling activity while its stock trades near its 52-week high of €37.64. Three high-ranking executives recently reduced their holdings in substantial
